Evidence map›Paper›PMID 41809819›Full record

ArticleFrontiers in oncology2026

Combined assessment of ERO1A expression and CD163

Tianyu Hong, Changjie Ren, Hao Xiang, Huaye Wu, Yongwei Yu, Mierxiati Abudurexiti, Zhong Wang, Chao Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tianyu Hong *School of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, Shanghai, China.
Changjie Ren *School of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, Shanghai, China.
Hao Xiang *The Third Affiliated Hospital of Zunyi Medical University, The First People's Hospital of Zunyi, Zunyi, Guizhou, China.
Huaye Wu *Department of Obstetrics and Gynecology, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Yongwei YuDepartment of Pathology, Changhai Hospital, Naval Medical University, Shanghai, China.
Mierxiati AbudurexitiSchool of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, Shanghai, China.
Zhong WangSchool of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, Shanghai, China.
Chao Wang *Department of Urinary Surgery, Pudong Gongli Hospital, Shanghai University of Medicine and Health Sciences, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The interplay between cancer cells and tumor-infiltrating immune cells (TIICs) facilitates the development of clear cell renal cell carcinoma (ccRCC). However, it remains unclear whether the combined assessment of tumor biomarkers and TIIC density increases the accuracy of ccRCC prognosis prediction. Methods: ERO1A expression was detected in ccRCC tissue samples and cell lines. ccRCC patients from two hospitals were recruited to investigate the value of ERO1A and other TIIC biomarkers in determining ccRCC prognosis via immunohistochemistry (IHC) and statistical analyses. Results: Compared with that in the corresponding controls, ERO1A expression in ccRCC cell lines and tissues was increased and closely correlated with ccRCC progression. ERO1A expression was positively correlated with the density of infiltrating CD163 Conclusions: Combining ERO1A expression, CD163 Précis: Compared with currently available biomarkers, the combination of ERO1A expression and the density of infiltrating CD163

Indexed as

CD163clear cell renal cell carcinomaERO1Aprognosistumor-associated macrophages

Identifiers

PMID41809819
PMCPMC12968006

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.